Search | Clinical Trials Finder

Conditions: Migraine
Interventions: TEZAMPANEL; Drug
Lead sponsor: TorreyPines Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Moderately to Severely Active Ulcerative Colitis
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 58
States / cities: Dothan, Alabama • Lancaster, California • Orange, California + 49 more

Conditions: Monitored Anesthesia Care
Interventions: arm 1, LUSEDRA, Propofol (arm 3); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Salt Lake City Utah, Utah

Conditions: Osteoporosis
Interventions: Romosozumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more

Conditions: LPL Deficiency
Interventions: alipogene tiparvovec, Prednisolone, Cyclosporins, Mycophenolate mofetil; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions: Self blood glucose monitoring and insulin administration, Standard care; Procedure
Lead sponsor: Atlanta VA Medical Center; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Alzheimer Disease, Dementia of Alzheimer Type
Interventions: PET/MR Imaging, 64Cu-FBP8; Diagnostic Test · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Arthritis, Rheumatoid
Interventions: GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 46
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more

Conditions: Dengue
Interventions: TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 20 Years to 49 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland • Silver Spring, Maryland

Conditions: Anxiety, Laceration Repair, Children
Interventions: iPad, Standard Care; Device · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 2 Years to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Breast Cancer
Interventions: TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets; Drug
Lead sponsor: Tolmar Inc.; Industry
Eligibility: 18 Years to 51 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 17
States / cities: Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more

Conditions: Influenza
Interventions: Peramivir 150 mg, Peramivir 300 mg, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 58
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 45 more

Conditions: Osteoarthritis
Interventions: Ketorolac Tromethamine Injection, Methylprednisolone Acetate Injection, Hylan G-F 20; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Hepatic Encephalopathy, Liver Cirrhosis, Portal Shunt Systemic
Interventions: Endoscopic ultrasound-guided transgastric embolization of the spontaneous portosystemic shunts, Interventional Radiology for shunt embolization/retrograde tranvenous obliteration; Procedure
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Contrast Enhancement in Magnetic Resonance Imaging, Children
Interventions: Gadoquatrane (BAY1747846); Drug
Lead sponsor: Bayer; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Indian Wells, California • Kansas City, Missouri • Charleston, South Carolina

Conditions: Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
Interventions: methotrexate, methotrexate - etanercept - prednisolone arm; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 2 Years to 17 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 12 more

Conditions: Prevention of Zika Infection, Zika-Specific Immune Response
Interventions: VRC-ZKADNA085-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 35 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Decatur, Georgia • Baltimore, Maryland • Bethesda, Maryland

Conditions: LCA5
Interventions: AAV8.hLCA5; Biological
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 4 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Interventions: Burosumab; Drug
Lead sponsor: Laura Tosi; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Metastatic Lobular Breast Carcinoma
Interventions: [68Ga]Ga DOTA-5G; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cervical Spine Fusion
Interventions: Bupivacaine Hcl 0.25% Inj, Normal saline; Drug · Other
Lead sponsor: Hartford Hospital; Other
Eligibility: 40 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Psoriasis
Interventions: Risankizumab-Rzaa, Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week 28 visit; Drug · Procedure
Lead sponsor: Jaehwan Kim; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Sacramento, California • New York, New York

Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Interventions: Sirolimus; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 56 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma
Interventions: bendamustine, bortezomib; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 13
States / cities: Encinitas, California • Roseville, California • San Diego, California + 10 more

Search by objective public record fields.

Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

Alipogene Tiparvovec for the Treatment of LPLD Patients

Inpatient Self Monitoring and Administration Study (ISMAS)

Assess Fibrin in Brains With AD/ADRD

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

iPad as a Distraction Tool During Facial Laceration Repair

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

Knee Injection RCT

Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy

A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

Burosumab for CSHS

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

Multifidus Cervicis Plane Block Vs. Sham Block For Posterior Cervical Spine Fusion Surgery

Risankizumab Long-term Remission Study

Sirolimus for Advanced Age-Related Macular Degeneration

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma